This is volume 5 of the series The History of Psychopharmacology and the CINP, As Told in Autobiography. It is a comprehensive cumulative index, and an appendix which includes a biographic register of all the contributors to the four main volumes.

Among the more frequently quoted epidemiological facts in current public health discussions are: (a) the elderly today represent about 10% of the population of the industrialized world; (b) the third world nations are moving in the same direction; (c) the trend toward a growing proportion of the aged in the world population will continue over the next few decades; (d) people over 80 now represent the fa. stest growing sector in North America; (e) in the elderly, general morbidity - and particularly morbidity of the central nervous syste- is many times that in the younger popUlation; (f) 5% of...

Joel Elkes was declared a "Pioneer of Psychopharmacology," at the XXIst CINP Congress in Glasgow in 1998. This prestigious award, one of many he has received, succinctly defines his groundbreaking contributions in laying the foundations for a discipline before even it existed. The papers included in this volume clearly reflect the visionary way in which Elkes firmly established the close integration of basic science and clinical research that are the hallmarks of modern psychopharmacology. A gifted scientist, innovative thinker, and dedicated teacher, his influence on the field has spanned...

This is volume 3 of the series The History of Psychopharmacology and the CINP, As Told in Autobiography. It covers the transformation of psychopharmacology to neuropsychopharacology in the 1980s and traces the story of the CINP during that period. This is a source book, based on a collection of memoirs of those who were there.

This is volume 4 of the series The History of Psychopharmacology and the CINP, As Told in Autobiography. The series covers in autobiographical accounts the fifty years that laid the foundation of neuropsychopharmacology In this fourth volume the story of the 1990s is complemented by reflections on twentieth-century psychopharmacology by the few of those who actively participated throughout the development of the field. The series represents the first source book for a field that has been virtually undocumented. Many of the stories have relevance to current research.

The development of modern psychopharmacology was triggered by two major discoveries: the psychomimetic effects of lysergic acid diethylamide (LSD-25) in 1943 and the therapeutic effects of chlorpromazine in 1952. In his opening address to the 1st CINP Congress in Rome, Rothlin pointed out that these discoveries gave "a great impetus for any kind of scientific approach to brain research" and had "revolutionary consequences in the treatment of psychotic patients." The incentive they provided "was not limited to theoretical and practical medical sciences but caused an even greater stimulus to...

This is volume 2 of the series The History of Psychopharmacology and the CINP, As Told in Autobiography. It covers the triumph of psychopharmacology in the 1970s and traces the story of the CINP during that period. This is a source book, based on a collection of memoirs of those who were there

Volume 1 of the series The History of Psychopharmacology and the CINP, As Told in Autobiography. It covers the rise of psychopharmacology and traces the history of the new field and of the CINP to about 1970. This is a source book, based on a collection of memoirs of those who were there.

This book consists of a collection of reviews prepared by basic scientists and clinicians involved in different areas of neuropsychopharmacology. The book focuses on the neurotransmitter era in neuropsychopharmacology.

Depressive illnesses, as epidemiological studies have consistently shown, are amongthe most frequent psychicdisorders encountered in hospital and everyday practice. Moreover, during the last few decades the prevalence of depression has definitely been increas ing. Its alarming frequency - especially among women - has re cently been confirmed once again by epidemiologicalfindings pub lished in the United States of America. The World Health Organi zation estimates the world-wide prevalence of depression at 3% to 5%. Amongthefactors contributingtothecurrentincreaseareexces sively abrupt changes...